155 related articles for article (PubMed ID: 12040357)
1. Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure.
Tauchert M
Am Heart J; 2002 May; 143(5):910-5. PubMed ID: 12040357
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of crataegus extract WS 1442 in congestive heart failure NYHA class II.
Zapfe jun G
Phytomedicine; 2001 Jul; 8(4):262-6. PubMed ID: 11515715
[TBL] [Abstract][Full Text] [Related]
3. Benefit-Risk Assessment of Crataegus Extract WSÂ 1442: An Evidence-Based Review.
Holubarsch CJF; Colucci WS; Eha J
Am J Cardiovasc Drugs; 2018 Feb; 18(1):25-36. PubMed ID: 29080984
[TBL] [Abstract][Full Text] [Related]
4. Prospective, comparative cohort studies and their contribution to the benefit assessments of therapeutic options: heart failure treatment with and without Hawthorn special extract WS 1442.
Habs M
Forsch Komplementarmed Klass Naturheilkd; 2004 Aug; 11 Suppl 1():36-9. PubMed ID: 15353901
[TBL] [Abstract][Full Text] [Related]
5. A randomised double blind placebo controlled clinical trial of a standardised extract of fresh Crataegus berries (Crataegisan) in the treatment of patients with congestive heart failure NYHA II.
Degenring FH; Suter A; Weber M; Saller R
Phytomedicine; 2003; 10(5):363-9. PubMed ID: 12833999
[TBL] [Abstract][Full Text] [Related]
6. [Crataegus Special Extract WS 1442. Assessment of objective effectiveness in patients with heart failure (NYHA II)].
Weikl A; Assmus KD; Neukum-Schmidt A; Schmitz J; Zapfe G; Noh HS; Siegrist J
Fortschr Med; 1996 Aug; 114(24):291-6. PubMed ID: 8974970
[TBL] [Abstract][Full Text] [Related]
7. [Crataegus Special Extract WS 1442 in NYHA II heart failure. A placebo controlled randomized double-blind study].
Leuchtgens H
Fortschr Med; 1993 Jul; 111(20-21):352-4. PubMed ID: 8375791
[TBL] [Abstract][Full Text] [Related]
8. Health effects of hawthorn.
Dahmer S; Scott E
Am Fam Physician; 2010 Feb; 81(4):465-8. PubMed ID: 20148500
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial.
Holubarsch CJ; Colucci WS; Meinertz T; Gaus W; Tendera M;
Eur J Heart Fail; 2008 Dec; 10(12):1255-63. PubMed ID: 19019730
[TBL] [Abstract][Full Text] [Related]
10. [Actions of standardized extracts of Crataegus berries on exercise tolerance and quality of life in patients with congestive heart failure].
Rietbrock N; Hamel M; Hempel B; Mitrovic V; Schmidt T; Wolf GK
Arzneimittelforschung; 2001 Oct; 51(10):793-8. PubMed ID: 11715631
[TBL] [Abstract][Full Text] [Related]
11. Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298].
Kasper S; Anghelescu IG; Szegedi A; Dienel A; Kieser M
BMC Med; 2006 Jun; 4():14. PubMed ID: 16796730
[TBL] [Abstract][Full Text] [Related]
12. Baseline severity but not gender modulates quantified Crataegus extract effects in early heart failure--a pooled analysis of clinical trials.
Eggeling T; Regitz-Zagrosek V; Zimmermann A; Burkart M
Phytomedicine; 2011 Nov; 18(14):1214-9. PubMed ID: 21784624
[TBL] [Abstract][Full Text] [Related]
13. Survival and prognosis: investigation of Crataegus extract WS 1442 in congestive heart failure (SPICE)--rationale, study design and study protocol.
Holubarsch CJ; Colucci WS; Meinertz T; Gaus W; Tendera M
Eur J Heart Fail; 2000 Dec; 2(4):431-7. PubMed ID: 11113721
[TBL] [Abstract][Full Text] [Related]
14. [High-dose Crataegus extract WS 1442 in the treatment of NYHA stage II heart failure].
Tauchert M; Gildor A; Lipinski J
Herz; 1999 Oct; 24(6):465-74; discussion 475. PubMed ID: 10546150
[TBL] [Abstract][Full Text] [Related]
15. Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials.
Pittler MH; Schmidt K; Ernst E
Am J Med; 2003 Jun; 114(8):665-74. PubMed ID: 12798455
[TBL] [Abstract][Full Text] [Related]
16. Hawthorn extract for treating chronic heart failure.
Pittler MH; Guo R; Ernst E
Cochrane Database Syst Rev; 2008 Jan; (1):CD005312. PubMed ID: 18254076
[TBL] [Abstract][Full Text] [Related]
17. Treatment of anxiety, tension and restlessness states with Kava special extract WS 1490 in general practice: a randomized placebo-controlled double-blind multicenter trial.
Gastpar M; Klimm HD
Phytomedicine; 2003 Nov; 10(8):631-9. PubMed ID: 14692723
[TBL] [Abstract][Full Text] [Related]
18. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group.
Erhardt L; MacLean A; Ilgenfritz J; Gelperin K; Blumenthal M
Eur Heart J; 1995 Dec; 16(12):1892-9. PubMed ID: 8682023
[TBL] [Abstract][Full Text] [Related]
19. Adverse-event profile of Crataegus spp.: a systematic review.
Daniele C; Mazzanti G; Pittler MH; Ernst E
Drug Saf; 2006; 29(6):523-35. PubMed ID: 16752934
[TBL] [Abstract][Full Text] [Related]
20. SAFETY AND EFFECTS OF
Niederseer D; Ledl-Kurkowski E; Kvita K; Funk P; Niebauer J
Acta Clin Croat; 2019 Dec; 58(4):604-614. PubMed ID: 32595244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
